<span item_type="fundamental" item_id="345e254ac49e7723ec2c29ec4f3a0539" counter_id="ST/US/CJMB" env="prod"></span><span item_type="announcement" item_id="632429121532987394" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 5.723 M.</p><p>EPS: As of FY2025, the actual value is USD -1.82.</p><p>EBIT: As of FY2025, the actual value is USD -7.041 M.</p><p></p><h3>Financial Highlights for the Full Year Ended December 31, 2025 vs. 2024</h3><h4>Revenue</h4><ul><li>Revenue for 2025 was $5.7 million, a decrease of $0.9 million from $6.6 million in 2024, primarily due to decreased demand for emergency preparedness services by certain states and local governments <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Cost of Revenues</h4><ul><li>Cost of revenues decreased by $0.4 million to $3.6 million in 2025 from $4 million in 2024, mainly attributed to the decrease in revenue <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Gross Profit</h4><ul><li>Gross profit decreased by $0.5 million, from $2.6 million in 2024 to $2.1 million in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Selling, General and Administrative (SG&amp;A) Expenses</h4><ul><li>SG&amp;A expenses increased by $3.8 million to $8.6 million in 2025 from $4.8 million in 2024, driven by professional fees for the Company’s initial public offering, becoming a public entity, and increased information technology support costs <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Impairment Loss on Property and Equipment</h4><ul><li>Callan JMB Inc. reported an impairment loss of $542,088 in 2025, compared to $0 in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Loss from Operations</h4><ul><li>Loss from operations was - $7.0 million in 2025, an increase from - $2.3 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Net Loss</h4><ul><li>Net loss for 2025 was - $7,966,366, compared to - $2,293,648 in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Cash and Cash Equivalents</h4><ul><li>Cash and cash equivalents were $2,130,758 as of December 31, 2025, a slight increase from $2,097,945 as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Net Cash Flow from Operating Activities</h4><ul><li>Net cash flow from operating activities was - $4,546,724 in 2025, a decrease from $540,353 in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Net Cash Flow from Investing Activities</h4><ul><li>Net cash flow from investing activities was - $616,896 in 2025, compared to - $46,167 in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h4>Net Cash Flow from Financing Activities</h4><ul><li>Net cash flow from financing activities was $5,196,433 in 2025, an increase from - $3,551,861 in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h3>Operational Metrics and Business Highlights</h3><ul><li>Callan JMB Inc. signed a manufacturing oversight, federal deployment, and commercialization agreement with Biostax Corp d/b/a Attune Biotech Inc. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>The Company established a joint venture with Revival Health to integrate logistics, shipping systems, bioservices, and data infrastructure <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>Callan JMB Services (India) Private Limited was launched with plans for a temperature-controlled warehouse in Pune, Maharashtra, for pharmaceutical storage and distribution <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>An agreement was secured with Walker’s Pharmaceuticals Ltd., and work is ongoing with other Indian companies to facilitate U.S. market entry and manufacturing plant establishment <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>A preliminary agreement was made with an oral drug delivery system maker to install manufacturing equipment in Callan JMB Inc.’s cGMP facility in Texas <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>The emergency preparedness contract with the City of Chicago was extended through June 2026, including a $1.5 million funding increase, raising the total contract value to $9.1 million <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>Callan JMB Inc. was awarded a second five-year contract by the Oregon Health Authority (OHA) for medical emergency preparedness and response services <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>The Company supported Texas and New Mexico in their measles outbreak response by redistributing MMR II vaccine doses from Chicago <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>A new comprehensive lease program for vaccine management was announced <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>Immunizations were successfully administered across 44 Tennessee counties through a partnership with Health Hero Tennessee <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>Callan JMB Inc. entered the food sampling sector by expanding its reclamation operations <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li><li>The proprietary Sentry Monitoring System was upgraded from Java to HTML5 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul><h3>Outlook</h3><ul><li>Callan JMB Inc. is focused on strengthening its core infrastructure, scaling readiness capabilities, and advancing strategic growth initiatives in high-velocity sectors like healthcare and food logistics for the remainder of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>. The Company is committed to long-term shareholder value creation by building a resilient, mission-driven organization <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>. This organization aims to be positioned at the center of critical healthcare and national preparedness supply chains <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2032545/000149315226014140/ex99-1.htm"></span>.</li></ul>

Callan Jmb | 8-K: FY2025 Revenue: USD 5.723 M